CA2546167A1 - Temporary absorbable venous occlusive device and superficial vein treatment method - Google Patents
Temporary absorbable venous occlusive device and superficial vein treatment method Download PDFInfo
- Publication number
- CA2546167A1 CA2546167A1 CA002546167A CA2546167A CA2546167A1 CA 2546167 A1 CA2546167 A1 CA 2546167A1 CA 002546167 A CA002546167 A CA 002546167A CA 2546167 A CA2546167 A CA 2546167A CA 2546167 A1 CA2546167 A1 CA 2546167A1
- Authority
- CA
- Canada
- Prior art keywords
- stent
- accordance
- vein
- stmt
- absorbable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/1204—Type of occlusion temporary occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0467—Instruments for cutting sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3954—Markers, e.g. radio-opaque or breast lesions markers magnetic, e.g. NMR or MRI
Abstract
A temporary absorbable venous occlusive stent (2) for use in a varicose vein treatment method includes a stent body (4), a bio-absorbable material associated with the body, and a closure (10) for blocking blood flow past the stent when implanted in a vein. The stent procedures localized blood clotting, fibrosis and vein collapse as it is absorbed. A permanent blockage is produced that prevents the undesirable back flow of blood from above the blockage site, thereby reducing distention of a varicose vein below the blockage site.
Description
TEMPORARY ABSORBABLE VENOUS OCCLUSIVE DEVICE AND SUPERFICIAL
VEIN TREATMENT METIiOD
to BACKGROUND OF THE INVENTION
Field of the Invention This invention relates to vascular disease and the treatment thereof. More particularly, the invention peitains to an apparatus and method for treating varicose 15 veins.
VEIN TREATMENT METIiOD
to BACKGROUND OF THE INVENTION
Field of the Invention This invention relates to vascular disease and the treatment thereof. More particularly, the invention peitains to an apparatus and method for treating varicose 15 veins.
2. Description of the Prior Art By way. of background,.the most common.technique for treating varicose veins is to remove one or more superficial blood vessels by way of surgical ligation and stripping. This technique suffers from the usual drawbacks associated with invasive 2o procedures, i.e., the need for hospitalization and surgery under general anesthesia, associated pain, infection risk, prolonged recovery time, limited mobility during recovery, permanent scarring, etc. More recently, an obliteration technique using high temperature radio frequency ablation has been proposed. According to this technique, a .
section of superficial vein is ablated so as to produce a blockage that prevents excessive 25 blood flow from above the treatment site, thereby reducing veiwdistension below the site. The radio' frequency ablatibn.technique represents an improvement over surgical ligation and stripping because it can be performed percutaneously as an ambulatory procedure. However, there is a risk that the high radio frequency energy could. damage tissue that surrounds the treated area if the procedure is not performed properly.
3o Moreover, the electronic equipment and procedural instrumentation required for the radio frequency technique are relatively costly. There is also no way to readily confirm that the treatment has been effective without the use of a venogram requiring dye injection and X-ray imaging.
It would be desirable if varicose veins could be treafed in a manner that overcomes the foregoing disadvantages of existing techniques.
SUMMARY OF THE INVENTION
The foregoing problems are solved and an advance in the art is obtained by a novel.temporary absorbable venous occlusive stent and a related varicose vein treatment method: The stmt includes a stmt body, a bio-absorbable material associated with the.
to body, and a closure for blocking blood flow past the stmt when irriplanted in a vein. The stmt promotes localized blood clotting, fibrosis and vein collapse as the stmt is absorbed. A permanent blockage is thereby produced that prevents the undesirable back flow of blood' from above the stent implantation site, thereby reducing distension of the varicose vein below the implantation site. .
15 According to the inventive treatment method, a temporary absorbable venous occlusive stmt is introduced via a deep venous system or superficial venous system approach to an implantation site proximate to or above a varicose vein to be treated.
There, the stent is deployed against the walls of the vein. Closure of the stmt is performed as necessary to block blood flow past the stent. As indicated above, the stmt 2o is gradually absorbed while producing a permanent blockage resulting from localized blood clotting, fibrosis and vein collapse.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the 25 invention, as illustrated in the accompanying Drawings, in which:
Fig. 1 is a diagrammatic view showing the outline of a human upper thigh and groin area and a portion of the venous circulatory system therein;
Fip. 2 is a perspective view showing a temporary absorbable venous occlusive stent in accordance with a first exemplary embodiment of the invention in various stages r 3o of closure;
section of superficial vein is ablated so as to produce a blockage that prevents excessive 25 blood flow from above the treatment site, thereby reducing veiwdistension below the site. The radio' frequency ablatibn.technique represents an improvement over surgical ligation and stripping because it can be performed percutaneously as an ambulatory procedure. However, there is a risk that the high radio frequency energy could. damage tissue that surrounds the treated area if the procedure is not performed properly.
3o Moreover, the electronic equipment and procedural instrumentation required for the radio frequency technique are relatively costly. There is also no way to readily confirm that the treatment has been effective without the use of a venogram requiring dye injection and X-ray imaging.
It would be desirable if varicose veins could be treafed in a manner that overcomes the foregoing disadvantages of existing techniques.
SUMMARY OF THE INVENTION
The foregoing problems are solved and an advance in the art is obtained by a novel.temporary absorbable venous occlusive stent and a related varicose vein treatment method: The stmt includes a stmt body, a bio-absorbable material associated with the.
to body, and a closure for blocking blood flow past the stmt when irriplanted in a vein. The stmt promotes localized blood clotting, fibrosis and vein collapse as the stmt is absorbed. A permanent blockage is thereby produced that prevents the undesirable back flow of blood' from above the stent implantation site, thereby reducing distension of the varicose vein below the implantation site. .
15 According to the inventive treatment method, a temporary absorbable venous occlusive stmt is introduced via a deep venous system or superficial venous system approach to an implantation site proximate to or above a varicose vein to be treated.
There, the stent is deployed against the walls of the vein. Closure of the stmt is performed as necessary to block blood flow past the stent. As indicated above, the stmt 2o is gradually absorbed while producing a permanent blockage resulting from localized blood clotting, fibrosis and vein collapse.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the 25 invention, as illustrated in the accompanying Drawings, in which:
Fig. 1 is a diagrammatic view showing the outline of a human upper thigh and groin area and a portion of the venous circulatory system therein;
Fip. 2 is a perspective view showing a temporary absorbable venous occlusive stent in accordance with a first exemplary embodiment of the invention in various stages r 3o of closure;
Fig. 3A is a longitudinal cross-sectional view of a varicose vein and a perspective view showing the stent of Fig. 2 being inserted therein;
Fig. 3B is a view according to Fig. 3A showing the stent in an initial deployed condition in the varicose vein;
5. Fig. 3C is a view according to Fig. 3A showing the stmt in a final deployed condition in the varicose vein;
Fig. 3D is a view according to Fig. 3A showing the stent in a partially absorbed condition and the varicose vein in a state of partial collapse;
Fig. 3E is a view according to Fig. 3A after the stmt has been completely absorbed and the varicose vein is fully collapsed and permanently blocked;
Fig. 4A is a perspective view of a temporary absorbable venous occlusive stmt in accordance with a second exemplary embodiment of the invention in which the stmt is formed as a generally tubular member having a closed end;
Fig. 4B is a perspective view according to Fig._4A in which the stmt is cross-1s sectionally divided to illustrate its.hollow interior;
Fig. 5A is a perspective view of a temporary absorbable venous occlusive stmt iri accordance with a third exemplary embodiment of the invention in which the stmt is formed as a solid member;
Fig. 5B is a perspective view according to Fig. 5A in which the stmt is cross-20 sectionally divided to illustrate its solid interior;
Fig. 6A is a longitudinal cross-sectional view showing a portion of a venous circulatory system in a human upper thigh and groin area and a perspective view of a stent delivery system including a guide wire that has been advanced from a percutaneous point of entry (not shown) to the site of a varicose vein to be implanted, and a sheath 25 introduces passing over the guide wire and approaching the sapheno-femoral junction;
Fig. 6B is a view according to Fig. 6A showing the sheath introduces after it has been advanced through the long saphenous vein (and any intervening superficial branch.
veins) to the site of the varicose vein to be implanted;.
Fig. 3B is a view according to Fig. 3A showing the stent in an initial deployed condition in the varicose vein;
5. Fig. 3C is a view according to Fig. 3A showing the stmt in a final deployed condition in the varicose vein;
Fig. 3D is a view according to Fig. 3A showing the stent in a partially absorbed condition and the varicose vein in a state of partial collapse;
Fig. 3E is a view according to Fig. 3A after the stmt has been completely absorbed and the varicose vein is fully collapsed and permanently blocked;
Fig. 4A is a perspective view of a temporary absorbable venous occlusive stmt in accordance with a second exemplary embodiment of the invention in which the stmt is formed as a generally tubular member having a closed end;
Fig. 4B is a perspective view according to Fig._4A in which the stmt is cross-1s sectionally divided to illustrate its.hollow interior;
Fig. 5A is a perspective view of a temporary absorbable venous occlusive stmt iri accordance with a third exemplary embodiment of the invention in which the stmt is formed as a solid member;
Fig. 5B is a perspective view according to Fig. 5A in which the stmt is cross-20 sectionally divided to illustrate its solid interior;
Fig. 6A is a longitudinal cross-sectional view showing a portion of a venous circulatory system in a human upper thigh and groin area and a perspective view of a stent delivery system including a guide wire that has been advanced from a percutaneous point of entry (not shown) to the site of a varicose vein to be implanted, and a sheath 25 introduces passing over the guide wire and approaching the sapheno-femoral junction;
Fig. 6B is a view according to Fig. 6A showing the sheath introduces after it has been advanced through the long saphenous vein (and any intervening superficial branch.
veins) to the site of the varicose vein to be implanted;.
Fig. 6C is a view according to Fig. 6A showing a balloon catheter carrying a temporary absorbable venous occlusive stmt within the sheath introduces, with the stmt approaching the sapheno-femoral junction;
Fig. 6D is a view according to Fig. 6A showing the stent at the distal end of the sheath introduces;
Fig. 6E is a view according to Fig. 6A showing the stmt following deployment in the .varicose vein to be implanted and expansion by the balloon catheter, and further showing withdrawal of the balloon catheter back into the sheath introduces;
Fig: 6F is a view according to Fig. 6A following removal of the balloon catheter to from the sheath introduces;
Fig. 6G is a view according to Fig: 6A showing the closure of the stent using drawstring members extending from the stent to the percutaneous entry point;
Fig. 6H is a view according to Fig. 6A following securement of the stmt drawstring members and cutting thereof proximate to the stmt;
15 Fig. 6I is a view according to Fig. 6A following removal of the sheath introduces;
Fig. 6J is a view according to Fig. 6A showing the stmt in a partially absorbed condition and the varicose vein in a state of partial collapse;
Fig. 6K is a view according to Fig. 6A after the stent has been fully absorbed and the implanted section of varicose vein is fully collapsed and permanently blocked;
20 Fig. 7 is a longitudinal cross-sectional view showing a portion of a venous circulatory system in a human upper thigh and groin area and a perspective view of a stent delivery system including a guide wire having a ferromagnetic tip that has been advanced at least partially under the guidance of a magnet from a percutaneous point of entry (not shown) to the site of a varicose vein to be implanted, and a sheath introduces 25 passing over the guide wire and approaching the sapheno-femoral junction;
and Fig. 8 is a longitudinal cross-sectional view showing a portion ~of a venous circulatory system in a human upper thigh and groin area and a.perspective view of a .
stmt delivery system including an sheath introduces having a ferromagnetic tip that has;~~
been guided at least partially by way of a magnet to the sapheno-femoral junction.
Fig. 6D is a view according to Fig. 6A showing the stent at the distal end of the sheath introduces;
Fig. 6E is a view according to Fig. 6A showing the stmt following deployment in the .varicose vein to be implanted and expansion by the balloon catheter, and further showing withdrawal of the balloon catheter back into the sheath introduces;
Fig: 6F is a view according to Fig. 6A following removal of the balloon catheter to from the sheath introduces;
Fig. 6G is a view according to Fig: 6A showing the closure of the stent using drawstring members extending from the stent to the percutaneous entry point;
Fig. 6H is a view according to Fig. 6A following securement of the stmt drawstring members and cutting thereof proximate to the stmt;
15 Fig. 6I is a view according to Fig. 6A following removal of the sheath introduces;
Fig. 6J is a view according to Fig. 6A showing the stmt in a partially absorbed condition and the varicose vein in a state of partial collapse;
Fig. 6K is a view according to Fig. 6A after the stent has been fully absorbed and the implanted section of varicose vein is fully collapsed and permanently blocked;
20 Fig. 7 is a longitudinal cross-sectional view showing a portion of a venous circulatory system in a human upper thigh and groin area and a perspective view of a stent delivery system including a guide wire having a ferromagnetic tip that has been advanced at least partially under the guidance of a magnet from a percutaneous point of entry (not shown) to the site of a varicose vein to be implanted, and a sheath introduces 25 passing over the guide wire and approaching the sapheno-femoral junction;
and Fig. 8 is a longitudinal cross-sectional view showing a portion ~of a venous circulatory system in a human upper thigh and groin area and a.perspective view of a .
stmt delivery system including an sheath introduces having a ferromagnetic tip that has;~~
been guided at least partially by way of a magnet to the sapheno-femoral junction.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIIVVIENTS
Turning now to Fig. 1, the thigh-groin region (TG) of a human leg is showy to illustrate a portion of the venous circulatory system and an exemplary area of the human body in which the present invention may be implemented. In particular, Fig. I
shows s the sapheno-femoral junction (SFJ) where many. of the superficial leg veins come together before joining the common femoral vein (CFA. Although not shown,, the, flow of blood at the aapheno-femoral junction is controlled by a ane-way valve that is designed to direct blood inwardly and upwardly, helping it return toward the heart. If this valve fails to function properly, some blood is able,to flow back down the leg, increasing the pressure in the superficial veins and their branches. . The long saphenous vein (LSV) is one of the main superficial veins in the thigh. If extra blood is forced into this vein by a leaking valve at the sapheno-femoral junction, the vein stretches and further valves within it become distorted and begin to leak. Blood is then able to flow further down the leg in the wrong direction, eventually filling and distending more and mare branches, causing the appearance of varicose veins, such as the varicose vein (W) shown in the inset in Fig. 1. Similar problems can occur due to valve leakage at the sapheno-popliteal junction of the short saphenous vein and, the popliteal vein behind the knee. Leakage of any of the valves in the perforator veins connecting the supe~cial leg veins to the deep veins of the leg can lil~ewise lead to varicose veins.
The present invention contemplates a varicose vein treatment apparatus and method wherein a distended varicose vein, such as the vein W of Fig. l, is implanted with a temporary absorbable venous occlusive stent. The stent is placed either within the distended area or into an adjacent (or non-adjacent) venous section that is delivering unwanted downward blood flow to the distended area. The stent stops the flow of blood 2s past the implantation site and promotes localized blood clotting,. fibrosis and vein collapse as the stmt is absorbed. Following complete absorption of the stent, a permanent blockage remains that prevents blood flow from above, thereby reducing or elirninating vein distention below the implantation site.
Fig. 2 illustrates an exemplary embodiment 2 of a temporary absorbable venous occlusive stmt that may be used in accordance with the invention. The stent Z
is configured as a generally tubular body .4 having a proximal end 6 and a distal end 8. The body 4 is made from a bio-absorbable material having the capability to absorb within a time frame that is long enough to allow the aforementioned permanent blockage to form in a vein to be implanted. By way of example only, a fabric woven from threads of dissolvable (e.g., poIylactic acid) suture material could be used to form the body 4. Such material has an absorption schedule of about 28 days, which should be more than adequate for purposes of the present invention. Both ends of the stmt 2 are initially open, but the proximal end 6 is.pxovided with a suitable closure system that allows into be closed following deployment.
Fig. 2 shows one exemplary closure system in the form of a drawstring arrangement. In particular, a drawstring 10 made from a dissolvable suture or other bio-absorbable material is secured around the circumferential periphery of the proximal end 6 of the body 4 in a manner that allows the proximal end to be closed by pulling an the drawstring's end portions 12 and 14. Although not shown, the drawstring 14 could likewise be placed at the distal end 8 of the .stent 2. It could also he arranged on the stmt 2 so that only a single drawstring end portion is required for stent closure.
Figs. 3A-3E illustrate a-series of the sequential steps by which the stent 2 can be used to treat a varicose vein. In Fig. 3A, the stmt 2 is in the process of being deployed to the varicose vein (VV) to be treated; with the stmt's proximal end being oriented toward its point of entry into the patient (not shown). In Fig. 3B, the stmt 2 is shown at an implantation site within the vein. . In Fig. 3C, the drawstring 10 has been manipulated to close the stmt's proximal end 6. At this point, blood flow is prevented from passing through the stmt 2, such that distention of the vein should be alleviated.
Closure of the stent 2 also causes blood in the vicinity of the stem to pool and begin.clotting. This produces fibrotic tissue and vein collapse as the stmt is absorbed: Fig. 3D
shows the stent 2 in a partially absorbed condition and the vein in a state of partial collapse. In Fig.
3E, the stent 2 is completely absorbed and the vein is fully collapsed and permanently blocked at 20. .The blockage 20 prevents the back flow of blood from leaky vein valves situated above the implantation site.
_'J_ It will be appreciated that many alternative constructions may be used to.provide a temporary absorbable venous occlusive stmt in accordance with tt~e invention. For example, such stems may be produced iri variety of diameters and lengths for implantation at different locations of the body. It may also be desirable to utilize several stents at a single implantation site in lieu of a single longer stent. In that case, the several stents could be provided with suitable connectors for establishing serial interconnections between adjacent stents. Stents in accordance with the invention can.
also be treated with a suitable drug, such as rapamycin (a cell cycle inhibitor). Such drug-alluded stems may be more efficient promoters of vein collapse than untreated to stems. Another alternative would be to treat a stmt with a suitable radioactive substance that produces localized cell death and an increased rate of vein.collapse.
Stents in accordance with the invention could be treated with drugs or radioactive substances by via impregnation into the bio-absorbable material that forms the stents.
Alternatively, the stents could be formed with a double lumen or the like to provide an.enclosed pocket is fox containing a drug or radioactive substance. Such a pocket could also be used to carry a cryomaterial that further promotes cell death and vein collapse. Another use for a pocket formed on the stmt would be to carry a dye material to guide stmt placement at an implantation site. Implantation could also be aided by providing the stmt with a radioopaque marker.
20 . Figs. 4A-4B and sA-SB illustrate additional stmt configuration alternatives. In Fig. 4A; a second exemplary embodiment 102 of a temporary absorbable venous occlusive stent is shown. As can be seen. with additional reference to Fig.
4B, the stmt 102 is configured as a generally tubular body 104 having a proximal end 106 and a distal end 108. The body 104 is similar to the body 4 of Fig. 2 except that the proximal end 2s 106 of the body 104 has a closed end wall 110. The end wall 110 provides a closure system for the stent 102 that represents an alternative to the drawstring closure system used in the scent 2 of Fig. 2. Note that the end wall 110 can either be permanently formed as part of the body 104, or alternatively could be separately attached thereto, either prior to, during or after deployment of the stent, 102 (e.g., as an insertable plug).
30 Although the end wall 110 is located at the proximal end 106 of the stmt 102, it could -$
also be located at the distal end 108. A wall could also be located at any point between the ends 106 and 108 of the stent 102, such as at the stent's longitudinal midpoint.
In Fig. 5A, a third exemplary .embodiment 202 of a temporary absorbable venous occlusive stent is shown. As can be seen with additional reference to Fig.SB, the stmt S 20-2 is configured as a generally solid cylindrical body 204 having a proximal end 206 and a distal end 208. The use of a solid body 204 provides a closure system for the stmt 202 that represents an alternative to the drawstring closure system used in the stmt 2 of Fig. 2. The body 204 can be made from any suitable bio-absorbable material, such as packed or bundled bio-absorbable filaments, folded bio-absorbable fabric, -or a bio-ta absorbable foam. Although the body 204 is shown as being generally cylindrical, it will appreciated that other configurations could also be used, such as spheres, cones, pyramids; irregular shapes, etc., to implement a body portion of the stmt 202.
Turning now to Figs. 6A-6K, an exemplary stmt implantation method utilizing pathways within a patient's deep vein system will now be described. It is assumed for 15 the purpose of illustration only that the temporary absorbable venous occlusive stent 2 of Fig. 2 is to be implanted in a varicose vein (VV) in one of the patient's legs. It is further . assumed that this vein can be reached via a common femoral vein (FV), a sapheno-femoral junction (SF~, a long.saphenous vein (LSV), and a possible intervening section (IS) that may contain one or more side branches of the type shown by reference numeral 2o (SB). According to the exemplary method, a percutaneous opening (not shown) is formed in the patient's cephalic vein located in the upper arm (or any other suitable location that allows access to the patient's deep venous system). Following vein entry, an optional guide wire is introduced and passed upwardly (e.g., using conventional optical guidance means as necessary) through the subclavian vein, there downwardly 25 through the superior vena cava and the inferior vena cava to a desired one of the femoral veins. Advancement'of the guide wire then continues along the selected femoral vein to the sapheno-femoral junction, at which point.the long saphenous vein is entered.. The guide wire is then further advanced along appropriate tributaries of the, long saphenous vein until the implantation site in the varicose vein (VV) is reached. As shown in Figs.
3o 6A and 6B, a sheath introducer is introduced over the guide wire and advanced along the venous pathways in which the guide wire is situated until the distal end of the introduces is adjacent to the implantation site: Alternatively, the sheath introduces can be inserted without the. use of a guide wire, or a guide wire could be inserted after the sheath introduces (in order to guide a balloon catheter as described below). In Figs.
6A and 6>3, .s the guide wire is designated by reference numeral 300 and the sheath iritroducer is designated by reference numeral 302.
Turning now to Figs. 6C arid 6D; the stmt 2 of Fig. 2 is mounted on an inflatable balloon dilator 304 situated.at the end of a balloon catheter 306, and the catheter is advanced over the guide wire 300 (if present) to the distal end of the sheath introduces to 302: Alternatively, the balloon dilator 304 and the stmt 2 could be positioned at the distal end of the sheath introduces 302 prior to the tatter's introduction into the patient, such that the stmt is carried with the sheath introduces to the implantation site: As can be further seen in Figs. 6C and 6D, the stent's drawstring ends 12 and 14 will extend back to the percutaneous entry site (not shown) as the stmt 2 is advanced into the Ls patient.
In Fig. 6E, the stmt 2 has been deployed out of the sheath introduces 302 by advancing the balloon catheter 306, the balloon dilator 304 has been dilated to expand the stent against the vein walls, and the balloon catheter is in the process of being removed from the stem. In Fig. 6F, the balloon cathetei 306 has been removed from the 20 introduces catheter 302. In Fig. 6G, the drawstring ends 12 and 14 have been manipulated to close the proximal end 6 of the stent 2. In Fig. 6H, the drawstring ends 12 and 14 have been cut near the stmt 2. In~Fig. 6I, the sheath introduces 302 has been removed from the patient. In Fig. 6J, the stent 2 is shown in the process of being absorbed at the implantation site as the vein collapses. In Fig. 6K, the absorption of the 2s stmt 2 is complete, the vein has fully collapsed, arid a permanent blockage 320 remains.
It will be appreciated that other stent implantation methods may be used in accordance with the present invention. For example, instead of approaching the implantation site via the deep venous system, a superficial venous approach could be used by entering one of the long or short saphenous veins either above or below the 3o implantation site, in relatively close proximity thereto. If such an entry point is used, an -lU-optional additional step that can be performed prior to cutting the drawstring ends 12 and 14 would be to suture one or both of therii to the patient's skin at the entry point. This will help stabilize the stmt 2 in its implantation position if such stabilization is desired.
Other stabilization techniques could also be used, such as~forming,the stmt 2 with a suitable surface-gripping configuration' or with other gripping means.
It will also be appreciated that the use of a balloon catheter as.per the exemplary method described above may not be necessary or desirable in all cases. For example, if a solid body stmt, such as the.stent 202 ofFigs. 5A and 5B is to be deployed, the use of a balloon catheter would not be indicated. In that case, the stmt could be carried to the to implantation site within an open-ended catheter (without a balloon dilator tip). A
plunger can then be used to force the stmt out of the catheter into engagement with the vein. Note that a stmt might also be constructed with resilient :properties so as to be outwardly expandable (e.g., using bio-absorbable foam). In that case, the steilt would be compressed while in the catheter but would expand to engage the vein walls when ~5 deployed.
Figs. 7 .and 8 show a further aspect of the invention in which a magnet 400 is used to direct either the guide wire 300 or the sheath introduces 302 (without a guide wire) to the implantation site in the varicose vein (W): In Fig. 7, the tip portion 402 of the guide wire 300 is made from ferromagnetic material. In Fig. 8, the tip of the sheath 20 . introducer.302 is provided with a ferromagnetic guide element 404. During treatment, a physician manipulates the magnet 400 over the surface of a patient's skin.
Because of the proximity of the supe~cial venous system to the skin's surface, the magnet 400 will impart a magnetic force on the guide wire tip 402 or the introduces guide element 404, thereby pulling the tip or guide. element in a direction determined by the magnet's 25 movement. In this way, and with the possible assistance of conventional optical guidance means, the stent 2 can be deployed to the desired location.
Accordingly, an apparatus and method for treating .varicose veins are disclosed.
While various embodiments of the invention have been shown and described, it should be apparent that many variations and alternative embodiments could be implemented in 30 accordance with the teachings herein. For example, although various bio-absorbable stent constructions have been described using bio-absorbable fabrics, filaments and foams, it will be appreciated that other bio-absorbable constructions may also be used for stents designed in accordance with the invention. Examples include solid surface materials that could be configured to form a stent using riiolding, milling or other fabrication techniques. It will be further appreciated that the stent.need not necessarily be 100% efficient at blocking blood flow. It is sufficient that there be enough blood flow suppression to induce clotting and fibrosis at the implantation site.
Belatedly, it is noted that not all portions of the stmt need to block blood flow so long as the stent.'s closure portion fulfills that function. Thus, side portions of the stmt that engage the to venous wall could potentially be porous to blood flow so long as the stmt's closure portion (e.g., an end wall) substantially blocks blood flow. It is understood, therefore, that the invention is not to be in any way limited except iri accordance with the spirit of the appended claims and their equivalents.
Turning now to Fig. 1, the thigh-groin region (TG) of a human leg is showy to illustrate a portion of the venous circulatory system and an exemplary area of the human body in which the present invention may be implemented. In particular, Fig. I
shows s the sapheno-femoral junction (SFJ) where many. of the superficial leg veins come together before joining the common femoral vein (CFA. Although not shown,, the, flow of blood at the aapheno-femoral junction is controlled by a ane-way valve that is designed to direct blood inwardly and upwardly, helping it return toward the heart. If this valve fails to function properly, some blood is able,to flow back down the leg, increasing the pressure in the superficial veins and their branches. . The long saphenous vein (LSV) is one of the main superficial veins in the thigh. If extra blood is forced into this vein by a leaking valve at the sapheno-femoral junction, the vein stretches and further valves within it become distorted and begin to leak. Blood is then able to flow further down the leg in the wrong direction, eventually filling and distending more and mare branches, causing the appearance of varicose veins, such as the varicose vein (W) shown in the inset in Fig. 1. Similar problems can occur due to valve leakage at the sapheno-popliteal junction of the short saphenous vein and, the popliteal vein behind the knee. Leakage of any of the valves in the perforator veins connecting the supe~cial leg veins to the deep veins of the leg can lil~ewise lead to varicose veins.
The present invention contemplates a varicose vein treatment apparatus and method wherein a distended varicose vein, such as the vein W of Fig. l, is implanted with a temporary absorbable venous occlusive stent. The stent is placed either within the distended area or into an adjacent (or non-adjacent) venous section that is delivering unwanted downward blood flow to the distended area. The stent stops the flow of blood 2s past the implantation site and promotes localized blood clotting,. fibrosis and vein collapse as the stmt is absorbed. Following complete absorption of the stent, a permanent blockage remains that prevents blood flow from above, thereby reducing or elirninating vein distention below the implantation site.
Fig. 2 illustrates an exemplary embodiment 2 of a temporary absorbable venous occlusive stmt that may be used in accordance with the invention. The stent Z
is configured as a generally tubular body .4 having a proximal end 6 and a distal end 8. The body 4 is made from a bio-absorbable material having the capability to absorb within a time frame that is long enough to allow the aforementioned permanent blockage to form in a vein to be implanted. By way of example only, a fabric woven from threads of dissolvable (e.g., poIylactic acid) suture material could be used to form the body 4. Such material has an absorption schedule of about 28 days, which should be more than adequate for purposes of the present invention. Both ends of the stmt 2 are initially open, but the proximal end 6 is.pxovided with a suitable closure system that allows into be closed following deployment.
Fig. 2 shows one exemplary closure system in the form of a drawstring arrangement. In particular, a drawstring 10 made from a dissolvable suture or other bio-absorbable material is secured around the circumferential periphery of the proximal end 6 of the body 4 in a manner that allows the proximal end to be closed by pulling an the drawstring's end portions 12 and 14. Although not shown, the drawstring 14 could likewise be placed at the distal end 8 of the .stent 2. It could also he arranged on the stmt 2 so that only a single drawstring end portion is required for stent closure.
Figs. 3A-3E illustrate a-series of the sequential steps by which the stent 2 can be used to treat a varicose vein. In Fig. 3A, the stmt 2 is in the process of being deployed to the varicose vein (VV) to be treated; with the stmt's proximal end being oriented toward its point of entry into the patient (not shown). In Fig. 3B, the stmt 2 is shown at an implantation site within the vein. . In Fig. 3C, the drawstring 10 has been manipulated to close the stmt's proximal end 6. At this point, blood flow is prevented from passing through the stmt 2, such that distention of the vein should be alleviated.
Closure of the stent 2 also causes blood in the vicinity of the stem to pool and begin.clotting. This produces fibrotic tissue and vein collapse as the stmt is absorbed: Fig. 3D
shows the stent 2 in a partially absorbed condition and the vein in a state of partial collapse. In Fig.
3E, the stent 2 is completely absorbed and the vein is fully collapsed and permanently blocked at 20. .The blockage 20 prevents the back flow of blood from leaky vein valves situated above the implantation site.
_'J_ It will be appreciated that many alternative constructions may be used to.provide a temporary absorbable venous occlusive stmt in accordance with tt~e invention. For example, such stems may be produced iri variety of diameters and lengths for implantation at different locations of the body. It may also be desirable to utilize several stents at a single implantation site in lieu of a single longer stent. In that case, the several stents could be provided with suitable connectors for establishing serial interconnections between adjacent stents. Stents in accordance with the invention can.
also be treated with a suitable drug, such as rapamycin (a cell cycle inhibitor). Such drug-alluded stems may be more efficient promoters of vein collapse than untreated to stems. Another alternative would be to treat a stmt with a suitable radioactive substance that produces localized cell death and an increased rate of vein.collapse.
Stents in accordance with the invention could be treated with drugs or radioactive substances by via impregnation into the bio-absorbable material that forms the stents.
Alternatively, the stents could be formed with a double lumen or the like to provide an.enclosed pocket is fox containing a drug or radioactive substance. Such a pocket could also be used to carry a cryomaterial that further promotes cell death and vein collapse. Another use for a pocket formed on the stmt would be to carry a dye material to guide stmt placement at an implantation site. Implantation could also be aided by providing the stmt with a radioopaque marker.
20 . Figs. 4A-4B and sA-SB illustrate additional stmt configuration alternatives. In Fig. 4A; a second exemplary embodiment 102 of a temporary absorbable venous occlusive stent is shown. As can be seen. with additional reference to Fig.
4B, the stmt 102 is configured as a generally tubular body 104 having a proximal end 106 and a distal end 108. The body 104 is similar to the body 4 of Fig. 2 except that the proximal end 2s 106 of the body 104 has a closed end wall 110. The end wall 110 provides a closure system for the stent 102 that represents an alternative to the drawstring closure system used in the scent 2 of Fig. 2. Note that the end wall 110 can either be permanently formed as part of the body 104, or alternatively could be separately attached thereto, either prior to, during or after deployment of the stent, 102 (e.g., as an insertable plug).
30 Although the end wall 110 is located at the proximal end 106 of the stmt 102, it could -$
also be located at the distal end 108. A wall could also be located at any point between the ends 106 and 108 of the stent 102, such as at the stent's longitudinal midpoint.
In Fig. 5A, a third exemplary .embodiment 202 of a temporary absorbable venous occlusive stent is shown. As can be seen with additional reference to Fig.SB, the stmt S 20-2 is configured as a generally solid cylindrical body 204 having a proximal end 206 and a distal end 208. The use of a solid body 204 provides a closure system for the stmt 202 that represents an alternative to the drawstring closure system used in the stmt 2 of Fig. 2. The body 204 can be made from any suitable bio-absorbable material, such as packed or bundled bio-absorbable filaments, folded bio-absorbable fabric, -or a bio-ta absorbable foam. Although the body 204 is shown as being generally cylindrical, it will appreciated that other configurations could also be used, such as spheres, cones, pyramids; irregular shapes, etc., to implement a body portion of the stmt 202.
Turning now to Figs. 6A-6K, an exemplary stmt implantation method utilizing pathways within a patient's deep vein system will now be described. It is assumed for 15 the purpose of illustration only that the temporary absorbable venous occlusive stent 2 of Fig. 2 is to be implanted in a varicose vein (VV) in one of the patient's legs. It is further . assumed that this vein can be reached via a common femoral vein (FV), a sapheno-femoral junction (SF~, a long.saphenous vein (LSV), and a possible intervening section (IS) that may contain one or more side branches of the type shown by reference numeral 2o (SB). According to the exemplary method, a percutaneous opening (not shown) is formed in the patient's cephalic vein located in the upper arm (or any other suitable location that allows access to the patient's deep venous system). Following vein entry, an optional guide wire is introduced and passed upwardly (e.g., using conventional optical guidance means as necessary) through the subclavian vein, there downwardly 25 through the superior vena cava and the inferior vena cava to a desired one of the femoral veins. Advancement'of the guide wire then continues along the selected femoral vein to the sapheno-femoral junction, at which point.the long saphenous vein is entered.. The guide wire is then further advanced along appropriate tributaries of the, long saphenous vein until the implantation site in the varicose vein (VV) is reached. As shown in Figs.
3o 6A and 6B, a sheath introducer is introduced over the guide wire and advanced along the venous pathways in which the guide wire is situated until the distal end of the introduces is adjacent to the implantation site: Alternatively, the sheath introduces can be inserted without the. use of a guide wire, or a guide wire could be inserted after the sheath introduces (in order to guide a balloon catheter as described below). In Figs.
6A and 6>3, .s the guide wire is designated by reference numeral 300 and the sheath iritroducer is designated by reference numeral 302.
Turning now to Figs. 6C arid 6D; the stmt 2 of Fig. 2 is mounted on an inflatable balloon dilator 304 situated.at the end of a balloon catheter 306, and the catheter is advanced over the guide wire 300 (if present) to the distal end of the sheath introduces to 302: Alternatively, the balloon dilator 304 and the stmt 2 could be positioned at the distal end of the sheath introduces 302 prior to the tatter's introduction into the patient, such that the stmt is carried with the sheath introduces to the implantation site: As can be further seen in Figs. 6C and 6D, the stent's drawstring ends 12 and 14 will extend back to the percutaneous entry site (not shown) as the stmt 2 is advanced into the Ls patient.
In Fig. 6E, the stmt 2 has been deployed out of the sheath introduces 302 by advancing the balloon catheter 306, the balloon dilator 304 has been dilated to expand the stent against the vein walls, and the balloon catheter is in the process of being removed from the stem. In Fig. 6F, the balloon cathetei 306 has been removed from the 20 introduces catheter 302. In Fig. 6G, the drawstring ends 12 and 14 have been manipulated to close the proximal end 6 of the stent 2. In Fig. 6H, the drawstring ends 12 and 14 have been cut near the stmt 2. In~Fig. 6I, the sheath introduces 302 has been removed from the patient. In Fig. 6J, the stent 2 is shown in the process of being absorbed at the implantation site as the vein collapses. In Fig. 6K, the absorption of the 2s stmt 2 is complete, the vein has fully collapsed, arid a permanent blockage 320 remains.
It will be appreciated that other stent implantation methods may be used in accordance with the present invention. For example, instead of approaching the implantation site via the deep venous system, a superficial venous approach could be used by entering one of the long or short saphenous veins either above or below the 3o implantation site, in relatively close proximity thereto. If such an entry point is used, an -lU-optional additional step that can be performed prior to cutting the drawstring ends 12 and 14 would be to suture one or both of therii to the patient's skin at the entry point. This will help stabilize the stmt 2 in its implantation position if such stabilization is desired.
Other stabilization techniques could also be used, such as~forming,the stmt 2 with a suitable surface-gripping configuration' or with other gripping means.
It will also be appreciated that the use of a balloon catheter as.per the exemplary method described above may not be necessary or desirable in all cases. For example, if a solid body stmt, such as the.stent 202 ofFigs. 5A and 5B is to be deployed, the use of a balloon catheter would not be indicated. In that case, the stmt could be carried to the to implantation site within an open-ended catheter (without a balloon dilator tip). A
plunger can then be used to force the stmt out of the catheter into engagement with the vein. Note that a stmt might also be constructed with resilient :properties so as to be outwardly expandable (e.g., using bio-absorbable foam). In that case, the steilt would be compressed while in the catheter but would expand to engage the vein walls when ~5 deployed.
Figs. 7 .and 8 show a further aspect of the invention in which a magnet 400 is used to direct either the guide wire 300 or the sheath introduces 302 (without a guide wire) to the implantation site in the varicose vein (W): In Fig. 7, the tip portion 402 of the guide wire 300 is made from ferromagnetic material. In Fig. 8, the tip of the sheath 20 . introducer.302 is provided with a ferromagnetic guide element 404. During treatment, a physician manipulates the magnet 400 over the surface of a patient's skin.
Because of the proximity of the supe~cial venous system to the skin's surface, the magnet 400 will impart a magnetic force on the guide wire tip 402 or the introduces guide element 404, thereby pulling the tip or guide. element in a direction determined by the magnet's 25 movement. In this way, and with the possible assistance of conventional optical guidance means, the stent 2 can be deployed to the desired location.
Accordingly, an apparatus and method for treating .varicose veins are disclosed.
While various embodiments of the invention have been shown and described, it should be apparent that many variations and alternative embodiments could be implemented in 30 accordance with the teachings herein. For example, although various bio-absorbable stent constructions have been described using bio-absorbable fabrics, filaments and foams, it will be appreciated that other bio-absorbable constructions may also be used for stents designed in accordance with the invention. Examples include solid surface materials that could be configured to form a stent using riiolding, milling or other fabrication techniques. It will be further appreciated that the stent.need not necessarily be 100% efficient at blocking blood flow. It is sufficient that there be enough blood flow suppression to induce clotting and fibrosis at the implantation site.
Belatedly, it is noted that not all portions of the stmt need to block blood flow so long as the stent.'s closure portion fulfills that function. Thus, side portions of the stmt that engage the to venous wall could potentially be porous to blood flow so long as the stmt's closure portion (e.g., an end wall) substantially blocks blood flow. It is understood, therefore, that the invention is not to be in any way limited except iri accordance with the spirit of the appended claims and their equivalents.
Claims (20)
1. A temporary absorbable venous occlusive stent, comprising:
a stent body;
a bio-absorbable material associated with said body; and closure means for blocking blood flow past said stent when implanted in a vein.
a stent body;
a bio-absorbable material associated with said body; and closure means for blocking blood flow past said stent when implanted in a vein.
2. A stent in accordance with claim 1 wherein said stent body is generally tubular.
3. A stent in accordance with claim 1 wherein said stent body is generally cylindrical.
4. A stent in accordance with claim 1 wherein said bio-absorbable material is provided. by a material used to form said stent body.
5. A stent in accordance with claim 1 wherein said bio-absorbable material comprises polylactic acid.
6. A stent in accordance with claim 1 wherein said closure means comprises a drawstring closure system at one end of said stent body.
7. A stent in accordance with claim 1 wherein said closure means comprises a drawstring closure system having a pair of drawstring ends.
8. A stent in accordance with claim 1 wherein said closure means comprises a closed end wall associated with said body.
9. A stent in accordance with claim 1 wherein said closure means comprises a closed end wall mounted on said body.
10. A stent in accordance with claim 1 wherein said closure means is provided by said stent body having a generally solid interior portion.
11. A method for treating a varicose vein, comprising:
introducing a temporary absorbable venous occlusive stent to an implantation site proximate to or above a varicose vein to be treated, said stent comprising:
a stent body;
a bio-absorbable material associated with said body; and closure means for blocking blood flow past said stent when implanted in a vein;
deploying said stent against a vein wall at said implantation site so as to block blood flow past said stent; and allowing said stent to form a blockage at said implantation site as said stent is absorbed.
introducing a temporary absorbable venous occlusive stent to an implantation site proximate to or above a varicose vein to be treated, said stent comprising:
a stent body;
a bio-absorbable material associated with said body; and closure means for blocking blood flow past said stent when implanted in a vein;
deploying said stent against a vein wall at said implantation site so as to block blood flow past said stent; and allowing said stent to form a blockage at said implantation site as said stent is absorbed.
12. A method in accordance with claim 11 wherein said stent is introduced via a deep venous system approach.
13. A method in accordance with claim 11 wherein said stent is introduced via cephalic vein approach.
14. A method in accordance with claim 11 wherein said stent is introduced via a superficial venous system approach.
15. A method in accordance with claim 11 wherein said stent is introduced via a sheath introducer.
16. A method in accordance with claim 11 wherein said stent is introduced via a sheath introducer and a guide wire.
17. A method in accordance with claim 11 wherein said stent is introduced by way of magnetic guidance.
18. A method in accordance with claim 11 wherein said stent is deployed using a balloon catheter.
19. A method in accordance with claim 11 wherein said stent is deployed using a balloon catheter and manipulation of said closure means.
20. A temporary absorbable venous occlusive stent; comprising:
a stent body comprising a bio-absorbable material; and a closure configuration associated with said stent body for blocking blood flow past said stent when implanted in a vein.
a stent body comprising a bio-absorbable material; and a closure configuration associated with said stent body for blocking blood flow past said stent when implanted in a vein.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52053003P | 2003-11-17 | 2003-11-17 | |
US60/520,530 | 2003-11-17 | ||
US10/754,919 | 2004-01-10 | ||
US10/754,919 US20050107867A1 (en) | 2003-11-17 | 2004-01-10 | Temporary absorbable venous occlusive stent and superficial vein treatment method |
PCT/US2004/038274 WO2005048884A1 (en) | 2003-11-17 | 2004-11-16 | Temporary absorbable venous occlusive device and superficial vein treatment method |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2546167A1 true CA2546167A1 (en) | 2005-06-02 |
Family
ID=34576962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002546167A Abandoned CA2546167A1 (en) | 2003-11-17 | 2004-11-16 | Temporary absorbable venous occlusive device and superficial vein treatment method |
Country Status (5)
Country | Link |
---|---|
US (4) | US20050107867A1 (en) |
EP (1) | EP1696834A1 (en) |
JP (1) | JP2007511294A (en) |
CA (1) | CA2546167A1 (en) |
WO (1) | WO2005048884A1 (en) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107867A1 (en) * | 2003-11-17 | 2005-05-19 | Taheri Syde A. | Temporary absorbable venous occlusive stent and superficial vein treatment method |
WO2005074845A1 (en) * | 2004-02-02 | 2005-08-18 | Ams Research Corporation | Enhancing tissue ingrowth for contraception |
US9713549B2 (en) * | 2004-02-02 | 2017-07-25 | Bayer Healthcare Llc | Contraceptive with permeable and impermeable components |
US8267985B2 (en) | 2005-05-25 | 2012-09-18 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
US7402320B2 (en) * | 2004-08-31 | 2008-07-22 | Vnus Medical Technologies, Inc. | Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure |
US8348858B2 (en) * | 2005-01-05 | 2013-01-08 | Stereotaxis, Inc. | Stent delivery guide wire |
US7972354B2 (en) * | 2005-01-25 | 2011-07-05 | Tyco Healthcare Group Lp | Method and apparatus for impeding migration of an implanted occlusive structure |
JP4945714B2 (en) | 2005-05-25 | 2012-06-06 | タイコ ヘルスケア グループ リミテッド パートナーシップ | System and method for supplying and deploying an occlusion device in a conduit |
US8273101B2 (en) | 2005-05-25 | 2012-09-25 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
DE102005032308A1 (en) * | 2005-07-11 | 2007-01-18 | Campus Gmbh & Co. Kg | Endovascular implant for the occlusion of a blood vessel |
US9017361B2 (en) * | 2006-04-20 | 2015-04-28 | Covidien Lp | Occlusive implant and methods for hollow anatomical structure |
US20080133040A1 (en) * | 2006-06-16 | 2008-06-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for specifying a blood vessel sleeve |
US8147537B2 (en) * | 2006-06-16 | 2012-04-03 | The Invention Science Fund I, Llc | Rapid-prototyped custom-fitted blood vessel sleeve |
US8550344B2 (en) * | 2006-06-16 | 2013-10-08 | The Invention Science Fund I, Llc | Specialty stents with flow control features or the like |
US7818084B2 (en) * | 2006-06-16 | 2010-10-19 | The Invention Science Fund, I, LLC | Methods and systems for making a blood vessel sleeve |
US8095382B2 (en) * | 2006-06-16 | 2012-01-10 | The Invention Science Fund I, Llc | Methods and systems for specifying a blood vessel sleeve |
US8478437B2 (en) * | 2006-06-16 | 2013-07-02 | The Invention Science Fund I, Llc | Methods and systems for making a blood vessel sleeve |
US8551155B2 (en) * | 2006-06-16 | 2013-10-08 | The Invention Science Fund I, Llc | Stent customization system and method |
US8163003B2 (en) * | 2006-06-16 | 2012-04-24 | The Invention Science Fund I, Llc | Active blood vessel sleeve methods and systems |
JP2010500915A (en) * | 2006-08-17 | 2010-01-14 | エヌフォーカス ニューロメディカル, インコーポレイテッド | Aneurysm isolation device |
US8784439B1 (en) * | 2006-11-28 | 2014-07-22 | Stephen V. Ward | Percutaneous medical procedures and devices for closing vessels using mechanical closures |
US20080215072A1 (en) * | 2007-02-15 | 2008-09-04 | Graham Kelly | Methods and apparatus for utilization of barbed sutures in human tissue including a method for eliminating or improving blood flow in veins |
US20090143815A1 (en) | 2007-11-30 | 2009-06-04 | Boston Scientific Scimed, Inc. | Apparatus and Method for Sealing a Vessel Puncture Opening |
EP3970633A1 (en) | 2008-04-21 | 2022-03-23 | Covidien LP | Braid-ball embolic devices and delivery systems |
US9675482B2 (en) | 2008-05-13 | 2017-06-13 | Covidien Lp | Braid implant delivery systems |
WO2009141591A1 (en) * | 2008-05-19 | 2009-11-26 | Jean-Pierre Lilley | Varicose vein treatment |
US8298466B1 (en) | 2008-06-27 | 2012-10-30 | Abbott Cardiovascular Systems Inc. | Method for fabricating medical devices with porous polymeric structures |
CN102137626A (en) | 2008-07-22 | 2011-07-27 | 微治疗公司 | Vascular remodeling device |
WO2010071856A1 (en) * | 2008-12-19 | 2010-06-24 | Tyco Healthcare Group, L.P. | Method and apparatus for storage and/or introduction of implant for hollow anatomical structure |
US20110202085A1 (en) * | 2009-11-09 | 2011-08-18 | Siddharth Loganathan | Braid Ball Embolic Device Features |
EP2528541B1 (en) | 2010-01-28 | 2016-05-18 | Covidien LP | Vascular remodeling device |
CN102740799A (en) | 2010-01-28 | 2012-10-17 | 泰科保健集团有限合伙公司 | Vascular remodeling device |
AU2012214240B2 (en) | 2011-02-11 | 2015-03-12 | Covidien Lp | Two-stage deployment aneurysm embolization devices |
US20120245674A1 (en) | 2011-03-25 | 2012-09-27 | Tyco Healthcare Group Lp | Vascular remodeling device |
US8577693B2 (en) | 2011-07-13 | 2013-11-05 | The Invention Science Fund I, Llc | Specialty stents with flow control features or the like |
WO2013049448A1 (en) | 2011-09-29 | 2013-04-04 | Covidien Lp | Vascular remodeling device |
EP2849725B1 (en) * | 2012-05-19 | 2020-11-25 | TARIS Biomedical LLC | Implantable urological device with improved retrieval feature |
US9155647B2 (en) | 2012-07-18 | 2015-10-13 | Covidien Lp | Methods and apparatus for luminal stenting |
US9314248B2 (en) | 2012-11-06 | 2016-04-19 | Covidien Lp | Multi-pivot thrombectomy device |
US9295571B2 (en) | 2013-01-17 | 2016-03-29 | Covidien Lp | Methods and apparatus for luminal stenting |
US9463105B2 (en) | 2013-03-14 | 2016-10-11 | Covidien Lp | Methods and apparatus for luminal stenting |
US8906086B2 (en) * | 2013-03-15 | 2014-12-09 | Cook Medical Technologies Llc | Endovascular stent graft with self-closing perfusion branch |
CN105142545B (en) | 2013-03-15 | 2018-04-06 | 柯惠有限合伙公司 | Locking device |
GB2516423B (en) | 2013-07-10 | 2015-07-15 | Cook Medical Technologies Llc | Vascular closure device |
GB2517169B (en) | 2013-08-13 | 2015-07-01 | Cook Medical Technologies Llc | Double baffle vascular occluder |
CN106659874B (en) | 2014-03-26 | 2021-01-05 | 文科罗斯公司 | Treatment of venous diseases |
US10478194B2 (en) | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
EP3243451B1 (en) * | 2016-05-12 | 2020-08-05 | IntelliStent AG | Device for adjustably restricting intravascular flow |
FR3060967A1 (en) * | 2016-12-22 | 2018-06-29 | Ass Marie Lannelongue | FLUIDIC OCCLUSION DEVICE BY CLOSING |
US11026693B2 (en) * | 2017-02-23 | 2021-06-08 | John S. DeMeritt | Endovascular occlusive device and associated surgical methodology |
US11191927B2 (en) | 2017-07-31 | 2021-12-07 | Boston Scientific Scimed, Inc. | Dilator with engagement region |
US11000287B2 (en) | 2017-08-15 | 2021-05-11 | Boston Scientific Scimed, Inc. | Occlusive medical device system |
US10874402B2 (en) | 2017-10-10 | 2020-12-29 | Boston Scientific Scimed, Inc. | Detachable RF energized occlusive device |
JP7034307B2 (en) | 2018-02-01 | 2022-03-11 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Medical device release system |
US11284902B2 (en) | 2018-02-01 | 2022-03-29 | Boston Scientific Scimed, Inc. | Method of making a vascular occlusion device |
US11109867B2 (en) | 2018-03-16 | 2021-09-07 | Boston Scientific Scimed, Inc. | Devices and methods for vein closure |
US11406540B2 (en) * | 2018-09-05 | 2022-08-09 | Acclarent, Inc. | Linked assembly with isthmus anchor for treating patulous eustachian tube |
US10959849B2 (en) | 2018-11-26 | 2021-03-30 | Joseph Martin Griffin | Device for percutaneous venous valve repair and related method |
US11672946B2 (en) | 2019-09-24 | 2023-06-13 | Boston Scientific Scimed, Inc. | Protection and actuation mechanism for controlled release of implantable embolic devices |
EP3906962A1 (en) * | 2020-05-07 | 2021-11-10 | Gefässpraxis Dr. Erpen AG | Device for closing the opening of a vein in the treatment of varicosis |
US20220047286A1 (en) * | 2020-08-11 | 2022-02-17 | Myodynamics, LLC | Medical device for snaring guidewire |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2733714A (en) * | 1956-02-07 | |||
US1941717A (en) * | 1933-08-09 | 1934-01-02 | Miriam E Rabell | Sanitary appliance |
US2286817A (en) * | 1940-01-04 | 1942-06-16 | Personal Products Corp | Tampon |
US2934068A (en) * | 1956-06-21 | 1960-04-26 | Personal Products Corp | Tow tampon |
US3177872A (en) * | 1962-11-23 | 1965-04-13 | Eastman Kodak Co | Vaginal tampon and applicator |
US3739773A (en) * | 1963-10-31 | 1973-06-19 | American Cyanamid Co | Polyglycolic acid prosthetic devices |
US3463158A (en) * | 1963-10-31 | 1969-08-26 | American Cyanamid Co | Polyglycolic acid prosthetic devices |
US3297033A (en) * | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
US3320956A (en) * | 1964-11-24 | 1967-05-23 | Johnson & Johnson | Catamenial tampon and method of making |
US3431909A (en) * | 1965-11-04 | 1969-03-11 | Scott Paper Co | Uncompressed tampon and applicator |
US3699965A (en) * | 1970-11-10 | 1972-10-24 | Int Playtex Corp | Tampon for absorbing body fluids |
US4002173A (en) * | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
US4027676A (en) * | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
US4185618A (en) * | 1976-01-05 | 1980-01-29 | Population Research, Inc. | Promotion of fibrous tissue growth in fallopian tubes for female sterilization |
US4173228A (en) * | 1977-05-16 | 1979-11-06 | Applied Medical Devices | Catheter locating device |
US4148317A (en) * | 1977-09-14 | 1979-04-10 | Personal Products Company | Reduced length tampon-applicator assembly |
US4509504A (en) * | 1978-01-18 | 1985-04-09 | Medline Ab | Occlusion of body channels |
US4268495A (en) * | 1979-01-08 | 1981-05-19 | Ethicon, Inc. | Injectable embolization and occlusion solution |
SE445884B (en) * | 1982-04-30 | 1986-07-28 | Medinvent Sa | DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION |
GB8304264D0 (en) * | 1983-02-16 | 1983-03-23 | Seedhom B B | Prosthetic ligament |
US4655777A (en) * | 1983-12-19 | 1987-04-07 | Southern Research Institute | Method of producing biodegradable prosthesis and products therefrom |
US4650488A (en) * | 1984-05-16 | 1987-03-17 | Richards Medical Company | Biodegradable prosthetic device |
US4700701A (en) * | 1985-10-23 | 1987-10-20 | Montaldi David H | Sterilization method and apparatus |
US5059211A (en) * | 1987-06-25 | 1991-10-22 | Duke University | Absorbable vascular stent |
US5527337A (en) * | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
US5254337A (en) * | 1987-06-30 | 1993-10-19 | Uop | Deodorizing compositions for animal grooming |
US5078744A (en) * | 1987-09-04 | 1992-01-07 | Bio-Products, Inc. | Method of using tendon/ligament substitutes composed of long, parallel, non-antigenic tendon/ligament fibers |
DE3730718A1 (en) * | 1987-09-12 | 1989-03-23 | Basf Ag | TETRACYCLIC CHINAZOLE DERIVATIVES, PRODUCTION AND USE |
US4916193A (en) * | 1987-12-17 | 1990-04-10 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
US5197983A (en) * | 1988-04-19 | 1993-03-30 | W. L. Gore & Associates, Inc. | Ligament and tendon prosthesis |
US5254105A (en) * | 1988-05-26 | 1993-10-19 | Haaga John R | Sheath for wound closure caused by a medical tubular device |
US4832055A (en) * | 1988-07-08 | 1989-05-23 | Palestrant Aubrey M | Mechanically locking blood clot filter |
US5634946A (en) * | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
AU4191989A (en) * | 1988-08-24 | 1990-03-23 | Marvin J. Slepian | Biodegradable polymeric endoluminal sealing |
US5328471A (en) * | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5085629A (en) * | 1988-10-06 | 1992-02-04 | Medical Engineering Corporation | Biodegradable stent |
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US5035706A (en) * | 1989-10-17 | 1991-07-30 | Cook Incorporated | Percutaneous stent and method for retrieval thereof |
CA2122041A1 (en) * | 1989-12-04 | 1993-04-29 | Kenneth Kensey | Plug device for sealing openings and method of use |
US5354295A (en) * | 1990-03-13 | 1994-10-11 | Target Therapeutics, Inc. | In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US6083220A (en) * | 1990-03-13 | 2000-07-04 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US5626863A (en) * | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
FR2668067B1 (en) * | 1990-10-23 | 1998-01-16 | Lg Medical Sa | SYRINGE FOR INJECTION OF A PRODUCT TOWARDS THE BODY OF A RECEIVER, PISTON FOR SYRINGE AND APPLICATION OF THIS SYRINGE TO THE INTRODUCTION OF A VASCULAR PROSTHESIS. |
US5133731A (en) * | 1990-11-09 | 1992-07-28 | Catheter Research, Inc. | Embolus supply system and method |
WO1992015342A1 (en) * | 1991-03-08 | 1992-09-17 | Keiji Igaki | Stent for vessel, structure of holding said stent, and device for mounting said stent |
US5425367A (en) * | 1991-09-04 | 1995-06-20 | Navion Biomedical Corporation | Catheter depth, position and orientation location system |
DE59202603D1 (en) * | 1991-09-13 | 1995-07-27 | Ciba Geigy Ag | Process for fixing dyes with UV light. |
US5304194A (en) * | 1991-10-02 | 1994-04-19 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5226911A (en) * | 1991-10-02 | 1993-07-13 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5266571A (en) * | 1992-01-09 | 1993-11-30 | Amer Moh Samir | Treatment of hemorrhoids with 5-HT2 antagonists |
US5489297A (en) * | 1992-01-27 | 1996-02-06 | Duran; Carlos M. G. | Bioprosthetic heart valve with absorbable stent |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
JPH05249052A (en) * | 1992-03-06 | 1993-09-28 | Nippon Sheet Glass Co Ltd | Flaw detector for light-transmitting plate material |
US5382261A (en) * | 1992-09-01 | 1995-01-17 | Expandable Grafts Partnership | Method and apparatus for occluding vessels |
AU4926193A (en) * | 1992-09-21 | 1994-04-12 | Vitaphore Corporation | Embolization plugs for blood vessels |
FR2696092B1 (en) * | 1992-09-28 | 1994-12-30 | Lefebvre Jean Marie | Kit for medical use composed of a filter and its device for placement in the vessel. |
US5382259A (en) * | 1992-10-26 | 1995-01-17 | Target Therapeutics, Inc. | Vasoocclusion coil with attached tubular woven or braided fibrous covering |
US5443458A (en) * | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
WO1994021197A1 (en) * | 1993-03-25 | 1994-09-29 | C.R. Bard, Inc. | Vascular graft |
CA2161776C (en) * | 1993-04-28 | 2005-12-20 | Chandrashekhar P. Pathak | Apparatus and methods for intraluminal photothermoforming |
US20030086975A1 (en) * | 2001-11-08 | 2003-05-08 | Timothy Ringeisen | Method for making a porous Polymeric material |
US5629077A (en) * | 1994-06-27 | 1997-05-13 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
US6123715A (en) * | 1994-07-08 | 2000-09-26 | Amplatz; Curtis | Method of forming medical devices; intravascular occlusion devices |
US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
GB9422571D0 (en) * | 1994-11-09 | 1995-01-04 | Whitehall Lab Ltd | Haemorrihoidal compositions and method of use |
US5609598A (en) * | 1994-12-30 | 1997-03-11 | Vnus Medical Technologies, Inc. | Method and apparatus for minimally invasive treatment of chronic venous insufficiency |
US5645558A (en) * | 1995-04-20 | 1997-07-08 | Medical University Of South Carolina | Anatomically shaped vasoocclusive device and method of making the same |
US6143007A (en) * | 1995-04-28 | 2000-11-07 | Target Therapeutics, Inc. | Method for making an occlusive device |
US6705323B1 (en) * | 1995-06-07 | 2004-03-16 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US5888546A (en) * | 1995-08-28 | 1999-03-30 | The Regents Of The University Of California | Embolic material for endovascular occlusion of abnormal vasculature and method for using the same |
US5601600A (en) * | 1995-09-08 | 1997-02-11 | Conceptus, Inc. | Endoluminal coil delivery system having a mechanical release mechanism |
US6090063A (en) * | 1995-12-01 | 2000-07-18 | C. R. Bard, Inc. | Device, system and method for implantation of filaments and particles in the body |
US5658308A (en) * | 1995-12-04 | 1997-08-19 | Target Therapeutics, Inc. | Bioactive occlusion coil |
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
US6638293B1 (en) * | 1996-02-02 | 2003-10-28 | Transvascular, Inc. | Methods and apparatus for blocking flow through blood vessels |
US20030229366A1 (en) * | 1996-02-02 | 2003-12-11 | Transvascular, Inc. | Implantable lumen occluding devices and methods |
US6949116B2 (en) * | 1996-05-08 | 2005-09-27 | Carag Ag | Device for plugging an opening such as in a wall of a hollow or tubular organ including biodegradable elements |
EP0900051A1 (en) * | 1996-05-08 | 1999-03-10 | Salviac Limited | An occluder device |
US6060534A (en) * | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6197983B1 (en) * | 1996-09-05 | 2001-03-06 | The Regents Of The University Of Michigan | Germanes and doping with germanes |
US7073504B2 (en) * | 1996-12-18 | 2006-07-11 | Ams Research Corporation | Contraceptive system and method of use |
US6096052A (en) * | 1998-07-08 | 2000-08-01 | Ovion, Inc. | Occluding device and method of use |
US6026814A (en) * | 1997-03-06 | 2000-02-22 | Scimed Life Systems, Inc. | System and method for percutaneous coronary artery bypass |
EP1005296B8 (en) * | 1997-06-05 | 2005-06-08 | Adiana, Inc. | Apparatus for tubal occlusion |
US6316522B1 (en) * | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
GB9717433D0 (en) * | 1997-08-19 | 1997-10-22 | Univ Nottingham | Biodegradable composites |
US6258084B1 (en) * | 1997-09-11 | 2001-07-10 | Vnus Medical Technologies, Inc. | Method for applying energy to biological tissue including the use of tumescent tissue compression |
US6401719B1 (en) * | 1997-09-11 | 2002-06-11 | Vnus Medical Technologies, Inc. | Method of ligating hollow anatomical structures |
US6120534A (en) * | 1997-10-29 | 2000-09-19 | Ruiz; Carlos E. | Endoluminal prosthesis having adjustable constriction |
AU739610B2 (en) * | 1997-11-07 | 2001-10-18 | Salviac Limited | Implantable occluder devices for medical use |
US6136015A (en) * | 1998-08-25 | 2000-10-24 | Micrus Corporation | Vasoocclusive coil |
US6626939B1 (en) * | 1997-12-18 | 2003-09-30 | Boston Scientific Scimed, Inc. | Stent-graft with bioabsorbable structural support |
US7070607B2 (en) * | 1998-01-27 | 2006-07-04 | The Regents Of The University Of California | Bioabsorbable polymeric implants and a method of using the same to create occlusions |
AU2565099A (en) * | 1998-01-27 | 1999-09-20 | Regents Of The University Of California, The | Biodegradable polymer/protein based coils for intralumenal implants |
US6254635B1 (en) * | 1998-02-02 | 2001-07-03 | St. Jude Medical, Inc. | Calcification-resistant medical articles |
US5935145A (en) * | 1998-02-13 | 1999-08-10 | Target Therapeutics, Inc. | Vaso-occlusive device with attached polymeric materials |
US6214047B1 (en) * | 1998-03-10 | 2001-04-10 | University Of Cincinnati | Article and method for coupling muscle to a prosthetic device |
US6465525B1 (en) * | 1998-03-18 | 2002-10-15 | Surmodics, Inc. | Latent reactive blood compatible agents |
WO1999051151A1 (en) * | 1998-04-07 | 1999-10-14 | Cook Incorporated | Vasoocclusive device including asymmetrical pluralities of fibers |
US7452371B2 (en) * | 1999-06-02 | 2008-11-18 | Cook Incorporated | Implantable vascular device |
GB9817128D0 (en) * | 1998-08-07 | 1998-10-07 | Lucas Ind Plc | Seal |
US6152943A (en) * | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
US6703047B2 (en) * | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
EP2138135B1 (en) * | 1998-09-08 | 2016-12-21 | Kabushikikaisha Igaki Iryo Sekkei | Stent for vessel |
DE69822470T2 (en) * | 1998-11-12 | 2005-01-20 | Takiron Co. Ltd. | Biodegradable absorbable shape memory material |
US20020065546A1 (en) * | 1998-12-31 | 2002-05-30 | Machan Lindsay S. | Stent grafts with bioactive coatings |
WO2000044309A2 (en) * | 1999-02-01 | 2000-08-03 | Board Of Regents, The University Of Texas System | Woven bifurcated and trifurcated stents and methods for making the same |
US7018401B1 (en) * | 1999-02-01 | 2006-03-28 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
US6368338B1 (en) * | 1999-03-05 | 2002-04-09 | Board Of Regents, The University Of Texas | Occlusion method and apparatus |
ES2295021T3 (en) * | 1999-03-25 | 2008-04-16 | Metabolix, Inc. | USE AND MEDICAL APPLICATIONS OF POLYMER POLYMERS (HYDROXIALCANOATS). |
US6645167B1 (en) * | 1999-05-21 | 2003-11-11 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an embolizing composition |
US7628803B2 (en) * | 2001-02-05 | 2009-12-08 | Cook Incorporated | Implantable vascular device |
US6375668B1 (en) * | 1999-06-02 | 2002-04-23 | Hanson S. Gifford | Devices and methods for treating vascular malformations |
US6499486B1 (en) * | 1999-07-29 | 2002-12-31 | Ethicon, Inc. | Method for reconstructing a ligament |
US6709667B1 (en) * | 1999-08-23 | 2004-03-23 | Conceptus, Inc. | Deployment actuation system for intrafallopian contraception |
US6602261B2 (en) * | 1999-10-04 | 2003-08-05 | Microvention, Inc. | Filamentous embolic device with expansile elements |
US6440164B1 (en) * | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US6338739B1 (en) * | 1999-12-22 | 2002-01-15 | Ethicon, Inc. | Biodegradable stent |
ATE357888T1 (en) * | 2000-02-03 | 2007-04-15 | Cook Inc | IMPLANTABLE VASCULAR DEVICE |
AU4566001A (en) * | 2000-03-13 | 2001-09-24 | Biocure Inc | Embolic compositions |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US7108721B2 (en) * | 2000-05-11 | 2006-09-19 | Massachusetts Institute Of Technology | Tissue regrafting |
SG98393A1 (en) * | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
US6974473B2 (en) * | 2000-06-30 | 2005-12-13 | Vascular Architects, Inc. | Function-enhanced thrombolytic AV fistula and method |
US6574851B1 (en) * | 2000-07-31 | 2003-06-10 | Advanced Cardiovascular Systems, Inc. | Stent made by rotational molding or centrifugal casting and method for making the same |
US8313504B2 (en) * | 2000-09-18 | 2012-11-20 | Cordis Corporation | Foam matrix embolization device |
US6726920B1 (en) * | 2000-09-22 | 2004-04-27 | Durect Corporation | Implantable drug delivery patch |
EP1399213A4 (en) * | 2000-10-11 | 2008-03-19 | Micro Therapeutics Inc | Methods for treating aneurysms |
US6565601B2 (en) * | 2000-11-15 | 2003-05-20 | Micro Therapeutics, Inc. | Methods for vascular reconstruction of diseased arteries |
US6846319B2 (en) * | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
US6623509B2 (en) * | 2000-12-14 | 2003-09-23 | Core Medical, Inc. | Apparatus and methods for sealing vascular punctures |
US20020143387A1 (en) * | 2001-03-27 | 2002-10-03 | Soetikno Roy M. | Stent repositioning and removal |
US20030004533A1 (en) * | 2001-05-04 | 2003-01-02 | Concentric Medical | Bioactive polymer vaso-occlusive device |
US20030004568A1 (en) * | 2001-05-04 | 2003-01-02 | Concentric Medical | Coated combination vaso-occlusive device |
CA2449055C (en) * | 2001-05-29 | 2010-03-02 | Microvention, Inc. | Method of manufacturing expansile filamentous embolization devices |
US6585754B2 (en) * | 2001-05-29 | 2003-07-01 | Scimed Life Systems, Inc. | Absorbable implantable vaso-occlusive member |
US20030069629A1 (en) * | 2001-06-01 | 2003-04-10 | Jadhav Balkrishna S. | Bioresorbable medical devices |
CA2452953A1 (en) * | 2001-07-18 | 2003-01-30 | The Research Foundation Of State University Of New York | Stent vascular intervention device and method |
US6592608B2 (en) * | 2001-12-07 | 2003-07-15 | Biopsy Sciences, Llc | Bioabsorbable sealant |
US20030044766A1 (en) * | 2001-08-29 | 2003-03-06 | Anne Scholz | Methods and devices for detecting cell-cell interactions |
TWI241199B (en) * | 2001-08-30 | 2005-10-11 | Ind Tech Res Inst | Method for manufacturing porous bioresorbable material having interconnected pores |
US20030093111A1 (en) * | 2001-10-26 | 2003-05-15 | Concentric Medical | Device for vaso-occlusion and interventional therapy |
US7192436B2 (en) * | 2001-11-08 | 2007-03-20 | Sub-Q, Inc. | Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
FR2832307B1 (en) * | 2001-11-19 | 2004-08-27 | Sofradim Production | DEVICE FOR OCCLUSIONING A BODILY CONDUIT, IN PARTICULAR A VARIOUS VEIN |
US6565521B1 (en) * | 2001-11-30 | 2003-05-20 | Silberg Barry N | System and method of vessel removal |
US7137993B2 (en) * | 2001-12-03 | 2006-11-21 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US8303625B2 (en) * | 2002-04-18 | 2012-11-06 | Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh | Biodegradable shape memory polymeric sutures |
US6916483B2 (en) * | 2002-07-22 | 2005-07-12 | Biodynamics, Llc | Bioabsorbable plugs containing drugs |
US7303575B2 (en) * | 2002-08-01 | 2007-12-04 | Lumen Biomedical, Inc. | Embolism protection devices |
US7674250B2 (en) * | 2002-08-05 | 2010-03-09 | Boston Scientific Scimed, Inc. | Methods of delivering therapeutic agents |
US7788130B2 (en) * | 2002-11-14 | 2010-08-31 | Kanoodle.Com, Inc. | Method and product for offering advertising services |
EP1610829B1 (en) * | 2003-04-04 | 2010-01-20 | Tissuemed Limited | Tissue-adhesive formulations |
US7879062B2 (en) * | 2003-07-22 | 2011-02-01 | Lumen Biomedical, Inc. | Fiber based embolism protection device |
WO2005034764A1 (en) * | 2003-09-12 | 2005-04-21 | Nmt Medical, Inc. | Device and methods for preventing formation of thrombi in the left atrial appendage |
WO2005030268A1 (en) * | 2003-09-25 | 2005-04-07 | Rutgers, The State University | Inherently radiopaque polymeric products for embolotherapy |
WO2005065079A2 (en) * | 2003-11-10 | 2005-07-21 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050107867A1 (en) * | 2003-11-17 | 2005-05-19 | Taheri Syde A. | Temporary absorbable venous occlusive stent and superficial vein treatment method |
EP1686903B1 (en) * | 2003-11-28 | 2014-07-30 | Cook Medical Technologies LLC | Vascular occlusion devices |
WO2005074845A1 (en) * | 2004-02-02 | 2005-08-18 | Ams Research Corporation | Enhancing tissue ingrowth for contraception |
US7402320B2 (en) * | 2004-08-31 | 2008-07-22 | Vnus Medical Technologies, Inc. | Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure |
JP2006198322A (en) * | 2005-01-24 | 2006-08-03 | Medicos Hirata:Kk | Intravascular embolus |
US20070056591A1 (en) * | 2005-09-15 | 2007-03-15 | Mcswain Hugh | Fallopian tube occlusion devices and methods |
-
2004
- 2004-01-10 US US10/754,919 patent/US20050107867A1/en not_active Abandoned
- 2004-11-16 EP EP04819147A patent/EP1696834A1/en not_active Withdrawn
- 2004-11-16 CA CA002546167A patent/CA2546167A1/en not_active Abandoned
- 2004-11-16 WO PCT/US2004/038274 patent/WO2005048884A1/en active Application Filing
- 2004-11-16 JP JP2006539989A patent/JP2007511294A/en not_active Withdrawn
-
2006
- 2006-04-20 US US11/407,847 patent/US20060282159A1/en not_active Abandoned
- 2006-04-20 US US11/407,689 patent/US20060282158A1/en not_active Abandoned
- 2006-04-20 US US11/407,482 patent/US20060190076A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050107867A1 (en) | 2005-05-19 |
WO2005048884A1 (en) | 2005-06-02 |
US20060190076A1 (en) | 2006-08-24 |
US20060282158A1 (en) | 2006-12-14 |
JP2007511294A (en) | 2007-05-10 |
EP1696834A1 (en) | 2006-09-06 |
US20060282159A1 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050107867A1 (en) | Temporary absorbable venous occlusive stent and superficial vein treatment method | |
US7169164B2 (en) | Apparatus for implanting devices in atrial appendages | |
US6464665B1 (en) | Catheter apparatus and method for arterializing a vein | |
EP3324863B1 (en) | Embolectomy system | |
US4923464A (en) | Percutaneously deliverable intravascular reconstruction prosthesis | |
JP2019515748A (en) | Internal carotid artery thrombectomy device and method | |
US20050234508A1 (en) | Blood vessel closure clip and delivery device | |
WO2004058097A2 (en) | Varying-diameter vascular implant and balloon | |
JP2000041988A (en) | Neovascularization catheter | |
EP1011458A2 (en) | Percutaneous bypass graft and securing system | |
JP2009034530A (en) | Dilating and support apparatus with disease inhibitors and methods for use | |
US20110270148A1 (en) | Percutaneous collateral bypass | |
WO2009099955A2 (en) | Vascular access to extra-vascular space | |
CN111743592A (en) | Aneurysm treatment device | |
WO2000057813A9 (en) | Angular vascular stent | |
WO2023100179A1 (en) | Embolus removal apparatus and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |